Contact
Please use this form to send email to PR contact of this press release:
Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation
TO:
Please use this form to send email to PR contact of this press release:
Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation
TO: